Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04559204
Other study ID # IIV4-PPV23
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date September 11, 2020
Est. completion date October 9, 2021

Study information

Verified date August 2022
Source China National Biotec Group Company Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Subjects will be recruited and divided into 3 groups: 1. Experimental Group (408 subjects): combined immunization of PPV23 and IIV4; 2. Control Group A (408 subjects): IIV4 only; 3. Control Group B (408 subjects): PPV23 only; All blood samples will be collected before and one month after vaccinatioin. The immunogenicity and safety of both experimental and control groups will be compared and the data be analyzed.


Description:

To evaluate the safety and immunogenicity of simultaneously immunization of 23-valent pneumococcal polysaccharide vaccine (PPV23) and quadrivalent inactivated influenza vaccine (IIV4) , we design this randomized, parallel controlled study . 1224 subjects are divided into 3 groups, including 1 experimental group and 2 control groups (control group A and B), each group includes 408 subjects respectively. Each 408-subject group is divided again into 4 age-based subgroups: ① 3-8 years old; ② 9-18 years old; ③ 19-49 years old ; ④ over 50 years old; each subgroup includes 102 subjects respectively. 408 subjects from experimental group will be simultaneously administrated with one dose of IIV (0.5 ml) and one dose of PPV23 (0.5 ml). Blood samples are collected before vaccination and one month (30 days) later. 408 subjects from control group A will be only administrated with one dose of IIV (0.5 ml). Blood samples are collected before vaccination and one month (30 days) later. 408 subjects from control group B will be only administrated with one dose of PPV23 (0.5 ml). Blood samples are collected before vaccination and one month (30 days) later. To evaluate the immunogenicity, we will detect and compare the neutralization antibody levels, the seroprotection rates, and antibody geometric mean concentrations. The safety of all groups will be monitored as well.


Recruitment information / eligibility

Status Completed
Enrollment 1224
Est. completion date October 9, 2021
Est. primary completion date November 26, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 3 Years and older
Eligibility Inclusion Criteria: - subjects aged no younger than 3 years old on the day of recruitment; - with valid informed consent signed by parent(s) or guardian(s); - parent(s) or guardian(s) are able to attend all scheduled appointments and comply with all study instructions; - subjects have not received any seasonal influenza vaccine or pneumonia vaccine before; - axillary temperature =37.0? Exclusion Criteria: - subject who has a medical history with hypersensitiveness, eclampsia, epilepsy, cerebropathia or neurological illness; - allergic to any ingredient of vaccine or with allergy history to any vaccine; - subjects with immunodeficency or suspected impairment of immunologic function (e.g. caused by HIV), or subjects are in the process of immunosuppressor therapy(taking orally injecting of steroid hormone); - administration of immunoglobulins within 30 days prior to this study; - acute febrile disease(temperature = 37.0°C) or infectious disease; - have a clearly diagnosed history of thrombocytopenia or other coagulopathy, which might cause contraindications for subcutaneous injection; - any serious chronic illness, acute infectious diseases, or respiratory diseases; severe cardiovascular disease, liver and kidney diseases or diabetes mellitus with complications; - any kind of infectious, purulent, or allergic skin diseases; - pregnant women and breastfeeding women; - inoculated with any vaccine within 14 days of the study; - any other factor that makes the investigator determines the subject is unsuitable for this study.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
IIV4 and PPV23
imultaneously immunization of 23-valent pneumococcal polysaccharide vaccine (PPV23) and quadrivalent inactivated influenza vaccine (IIV4)
IIV4
administrated with IIV4 only
PPV23
administrated with PPV23 only

Locations

Country Name City State
China Qidong County Center for Disease Control and Prevention Qidong Hunan
China Qingzhen Center for Disease Control and Prevention Qingzhen Guizhou
China Liucheng Community Health Services Center Quanzhou Fujian
China Luodong County Health Center Quanzhou Fujian

Sponsors (8)

Lead Sponsor Collaborator
China National Biotec Group Company Limited Changchun Institute of Biological Products Co., Ltd., Chengdu Institute of Biological Products Co.,Ltd., Fujian Provincial Center for Disease Control and Prevention, Guizhou Center for Disease Control and Prevention, Hunan Provincial Center for Disease Control and Prevention, National Institutes for Food and Drug Control, China, Peking University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Seroconversion rate (IIV4) the rate of positive seroconversion against influenza A (H3N2, H1N1) type and B (BY, BV) type viruses Baseline (before vaccination) results
Primary Seroconversion rate (IIV4) the rate of positive seroconversion against influenza A (H3N2, H1N1) type and B (BY, BV) type viruses Results obtained 1 month after vaccination
Primary Seroconversion rate (PPV23) the rate of positive seroconversion against 23 pneumococcal serotypes Baseline (before vaccination) results
Primary Seroconversion rate (PPV23) the rate of positive seroconversion against 23 pneumococcal serotypes Results obtained 1 month after vaccination
Primary Geometric Mean Concentration (GMC) (IIV4) GMCs of influenza A (H3N2, H1N1) type and B (BY, BV) type viruses Baseline (before vaccination) results
Primary Geometric Mean Concentration (GMC) (IIV4) GMCs of influenza A (H3N2, H1N1) type and B (BY, BV) type viruses Results obtained 1 month after vaccination
Primary Geometric Mean Concentration (GMC) (PPV23) GMCs of 23 pneumococcal serotypes Baseline (before vaccination) results
Primary Geometric Mean Concentration (GMC) (PPV23) GMCs of 23 pneumococcal serotypes Results obtained 1 month after vaccination
Secondary adverse events following vaccination analyse the incidence of adverse events following immunization, both solicited and unsolicited 0-1 month (30 days)
See also
  Status Clinical Trial Phase
Completed NCT03442582 - Afluria Pregnancy Registry
Completed NCT03275389 - A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years Phase 1
Completed NCT05981846 - A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19 Phase 2
Completed NCT05044195 - A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age Phase 3
Completed NCT02914275 - A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age. Phase 3
Completed NCT04590066 - Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy N/A
Recruiting NCT03778203 - Development of Childhood Anti-influenza Immunity Phase 4
Completed NCT04527614 - Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection N/A
Terminated NCT03658629 - Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults Phase 2
Completed NCT05269290 - Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections Phase 3
Completed NCT06385821 - A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus Phase 3
Completed NCT02998996 - Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU Phase 1/Phase 2
Completed NCT02984280 - Specific Respiratory Infections as Triggers of Acute Medical Events N/A
Completed NCT02867358 - A Clinical Trial of KT07 Capsule in the U.S.A Phase 2
Withdrawn NCT02883972 - Childhood Influenza Immunisation Invitation Trial in Schools N/A
Completed NCT02545543 - A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age Phase 3
Completed NCT02243774 - Mail Outreach To Increase Vaccination Acceptance Through Engagement N/A
Completed NCT02212106 - A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years Phase 4
Completed NCT02621164 - Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents Phase 3
Completed NCT02344134 - Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly Subjects Phase 3